Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04237207 · ClinicalTrials.gov registry record · NA
Clinical Evaluation of a Cochlear Implant Sound Processor
A NA study of Hearing Loss and Hearing Disorders, sponsored by Advanced Bionics.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 6
- Study locations
NCT04237207: Completed NA study of Hearing Loss and Hearing Disorders, sponsored by Advanced Bionics.
NCT04237207 is a NA study of Hearing Loss and Hearing Disorders that has completed, run by Advanced Bionics. The registered enrollment target is 22 participants, below the 6,121-participant average among 58 other Hearing Loss trials with a reported enrollment target (100% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04237207, a NA study of Hearing Loss and Hearing Disorders, has completed, sponsored by Advanced Bionics.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a prospective within-subjects repeated-measures study that will enroll 24 adult users implanted with a HiResolution Bionic Ear System (HiRes 90K or newer). Subjects will be assigned to one of two cohorts based on audiometric results at the Baseline visit
Primary Outcome
The primary efficacy endpoints are AzBio sentence recognition scores in quiet at Baseline with the new sound processor as compared to AzBio sentence recognition scores in quiet at Baseline with currently approved software on a Q90 processor. Scores are determined on a scale of 0% to 100% words correct with higher scores indicating a better outcome.
Conditions Studied
Interventions
- DEVICE Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software
- DEVICE 301-M062 sound processor & software
Study Locations (6)
Missouri
- Midwest Ear Institute/St. Luke's Health System - Kansas City
- Washington University Medical Center - St Louis
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Florida
- Tampa Bay Hearing and Balance Center - Tampa
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- Austin Ear, Nose & Throat Clinic - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-12-17 |
| Est. Completion | 2020-10-15 |
| Phase | NA |
What the finished NCT04237207 record still lists
NCT04237207 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 6,121-participant average among 58 other Hearing Loss trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Hearing Loss appearing as the primary indexed condition, and to 2 interventions - of which Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software is the first listed.
NCT04237207 lists 6 locations in 5 states (Missouri, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT04237207 about?
NCT04237207 is a clinical study titled "Clinical Evaluation of a Cochlear Implant Sound Processor". This is a prospective within-subjects repeated-measures study that will enroll 24 adult users implanted with a HiResolution Bionic Ear System (HiRes 90K or newer). Subjects will be assigned to one of two cohorts based on audiometric results at the Baseline visit
What is the current status of trial NCT04237207?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2019-12-17. Estimated completion is 2020-10-15.
What conditions does trial NCT04237207 study?
This clinical trial studies the following conditions: Hearing Loss, Hearing Disorders, Ear Diseases, Otorhinolaryngologic Diseases.
What interventions are being tested in trial NCT04237207?
The interventions under investigation include: Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software (DEVICE), 301-M062 sound processor & software (DEVICE).
Who is sponsoring clinical trial NCT04237207?
This trial is sponsored by Advanced Bionics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04237207 being conducted?
This trial has 6 study locations across Colorado, Florida, Missouri, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hearing Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04237207's enrollment target sits among peer trials
22 55th of 58 higher than 4 of 58 other Hearing Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hearing Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Access and Affordability of Adult Hearing Healthcare
RECRUITING · NA
-
AI Noise Reduction in Phonak Hearing Aids
RECRUITING · NA
-
Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation
RECRUITING · NA
-
Auditory-Cognitive Training to Optimize Outcomes for Older CI Users
RECRUITING · NA
-
Innovations in Hearing Accessibility and Technology (IHAT) Study
RECRUITING · NA
-
Clinical Utility of Residual Hearing in the Cochlear Implant Ear
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI